Many studies have verified the breast cancer stem cell line with the CD44+/CD24-/ALDH+ marker, and recently the high expression of aldehyde dehydrogenase (ALDH+) was associated to therapeutic resistance. The gene discussed is CD44; the disease is breast carcinoma.